Immuron Grows Sales 5% to $4.2M and Wins FDA Approval for C. Diff Trial

Immuron delivers 5% global sales growth and secures FDA approval for C. diff drug trial

Immuron has reported the Immuron HY26 Strategic Reset Results in a strategic update covering the first half of FY26, with global sales reaching $4.2 million (up 5% year-on-year) and cash reserves of $10.0 million providing approximately 23.5 months of operating runway. The commercial-stage biopharmaceutical company (ASX: IMC) has combined revenue growth with clinical progress, securing FDA approval in November 2025 for its IMM-529 Investigational New Drug (IND) application targeting Clostridioides difficile infection.

The company’s dual revenue model is positioning it as a rare example of a biotech generating commercial income whilst advancing a high-value clinical pipeline. Australian sales grew 13% to $3.3 million, whilst USA sales increased 17% year-on-year, offsetting a temporary decline in Canada due to prior-year inventory timing.

Management has stated it aims to deliver Net Sales, Net Profit, and EBITDX (ex-R&D) in H2 FY26 that exceed the prior corresponding period. The company raised $7.3 million (net) in capital during the period at an average price of A$0.0803 per share, supporting its partnering strategy for clinical advancement.

What is Immuron’s hyper-immune platform and why does it matter?

Immuron’s core technology centres on programming cows through vaccination to produce high levels of specific antibodies (immunoglobulins). These bovine antibodies are collected via colostrum and processed into oral therapies that survive the harsh acidic environment of the human stomach to work directly in the gastrointestinal tract.

Unlike most antibody therapies that require injection, Immuron’s oral delivery mechanism creates a significant competitive advantage. The platform is described as “tuneable,” allowing the company to target different pathogens by changing the vaccine used in the bovine immunisation process. The products employ a dual-action mechanism, preventing pathogens from adhering to the gut wall whilst neutralising inflammatory toxins they release.

The platform’s safety profile has been demonstrated across more than 700 adults and children (ages 6-19) treated in multiple studies, including doses up to 3,600 mg/day for 24 weeks. No serious adverse events have been attributed to the treatment. Safety has been confirmed through repeat-dose animal toxicity studies, immunohistochemical assessments showing no off-target cross-reactivity, and bacterial reverse-mutation testing confirming it is non-mutagenic.

Key Platform Advantages:

• Oral delivery bypasses injection requirements
• Precision targeting through customisable vaccination protocols
• Dual-action mechanism (adhesion prevention and toxin neutralisation)
• Proven safety profile with no serious adverse events reported

Regional performance shows US momentum despite Canada timing

Australian operations delivered the strongest growth, with sales of $3.3 million (up 13% year-on-year) maintaining the company’s dominant position in its home market. North American sales totalled $0.9 million, down 18% overall, but this decline masks divergent regional performance.

USA sales specifically grew 17% year-on-year to $0.9 million, demonstrating accelerating market penetration. The North American decline is attributed entirely to Canada, where FY25 saw a Q1 pipeline fill into over 1,000 retail doors following secured listings within key pharmacy and grocery retail groups. As anticipated, Canadian sales recovered in Q2 FY26, posting 191% quarter-on-quarter growth.

Post-period, the company secured distribution with Jean Coutu, Quebec’s largest pharmacy chain, which management expects to drive H2 FY26 revenue growth. The company maintained a gross profit margin of 63% across all regions.

FDA greenlights IMM-529 trial for C. diff infection

In November 2025, the FDA approved Immuron’s IND application for IMM-529 (IND 32095), enabling clinical development to proceed for a product targeting Clostridioides difficile infection. C. diff is a serious bacterial infection that frequently follows antibiotic use, with Immuron citing estimated peak US sales opportunity of US$400 million based on Lumanity global healthcare consulting analysis.

The company has elected to seek partners to advance both IMM-529 and IMM-124E (Travelan) clinical programmes rather than self-funding development. For IMM-124E, Immuron has deferred its end of Phase 2 meeting request with the FDA pending discussions with potential partners.

The Uniformed Services University (USU) clinical trial for Travelan reported results in December 2025. The primary endpoint did not reach statistical significance, but the company attributed this to the investigational product being manufactured by a third party and not administered in accordance with Travelan’s directions for use. Management stated that the clinically validated three-times-daily dosing schedule would be discussed at an end-of-Phase 2 meeting with the FDA.

Clinical Pipeline Status:

1. IMM-124E (Travelan) – End of Phase 2 meeting deferred pending partner discussions; clinical study report submitted to FDA in January 2025
2. IMM-529 (C. diff) – IND approved November 2025; seeking partners to advance development
3. IMM-986 (VRE) – Deprioritised following preclinical evaluation; company electing not to fund further development to prioritise partnering more advanced programmes

Supply chain advantage from BSE-free sourcing

All colostrum used in Immuron’s products is sourced exclusively from Australia and New Zealand, the only Category 1 BSE-free regions globally. This sourcing strategy addresses a key risk factor for biologics investors and supports international regulatory pathways.

Manufacturing occurs under Good Manufacturing Practice (GMP) standards compliant with FDA, Health Canada, and TGA requirements. The active pharmaceutical ingredient (API) is non-GMO, Kosher, and Halal certified, which the company states facilitates smoother market entry in multiple jurisdictions compared to synthetic drugs, as it is classified under dairy food ingredient regulations.

What’s next for Immuron shareholders

Management is targeting H2 FY26 and full FY26 Net Sales to exceed the prior corresponding period, with Net Sales, Net Profit, and EBITDX (ex-R&D) all projected to exceed prior year levels. EBITDX (ex-R&D) improved by $0.7 million compared to H2 FY25, reaching $(1.1) million for H1 FY26.

The company’s cash position of $10.0 million provides approximately 23.5 months of runway based on H1 FY26 cash used in operating activities, calculated for illustrative purposes. This runway is intended to support the partnering strategy for both clinical programmes without immediate dilution risk.

Forward Catalysts:

• Jean Coutu distribution rollout in Canada (H2 FY26)
• Partner discussions for IMM-124E and IMM-529 clinical advancement
• Continued US market expansion with existing commercial products
• ProIBS product launch in Australia (generated $72,000 in H1 FY26 sales)

Could Immuron’s FDA-Approved C. diff Programme Unlock Significant Shareholder Value?

With FDA approval secured for its IMM-529 clinical trial and commercial sales generating consistent cash flow, Immuron is positioning itself as a rare biotech combining revenue growth with high-value pipeline advancement. The company’s dual-action oral delivery platform addresses a US$400 million peak sales opportunity in C. diff infection whilst maintaining 23.5 months of operating runway.

Investors seeking exposure to a commercial-stage biopharmaceutical with regulatory momentum and expanding North American distribution can visit the Immuron investor centre to explore the company’s partnering strategy and clinical milestones. The company’s financial position and product pipeline offer a detailed case study in biotech value creation.